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Background: Daytime and nighttime sleep disturbances and cognitive impairment occur frequently in
Parkinson’s disease (PD), but little is known about the interdependence of these non-motor complica-
tions. Thus, we examined the relationships among excessive daytime sleepiness, nighttime sleep quality
and cognitive impairment in PD, including severity and speciﬁc cognitive deﬁcits.
Methods: Ninety-three PD patients underwent clinical and neuropsychological evaluations including the
Epworth Sleepiness Scale (ESS) and Pittsburgh Sleep Quality Index (PSQI). Patients were classiﬁed as
having normal cognition (PD-NC), mild cognitive impairment (PD-MCI), or dementia (PDD) using
recently proposed Movement Disorder Society PD-MCI and PDD criteria. Relationships between the sleep
and cognitive measures and PD cognitive groups were examined.
Results: The PD cohort included PD-NC (n ¼ 28), PD-MCI (n ¼ 40), and PDD (n ¼ 25) patients. ESS scores,
as a measure of daytime sleepiness, were signiﬁcantly worse (p ¼ 0.005) in cognitively impaired PD
patients, particularly PDD patients. ESS scores correlated signiﬁcantly with Mini-Mental State Exami-
nation scores and also with cognitive domain scores for attention/working memory, executive function,
memory, and visuospatial function. In contrast, PSQI scores, as a measure of nighttime sleep quality,
neither differed among cognitive groups nor correlated with any cognitive measures.
Conclusions: Daytime sleepiness in PD, but not nighttime sleep problems, is associated with cognitive
impairment in PD, especially in the setting of dementia, and attention/working memory, executive
function, memory, and visuospatial deﬁcits. The presence of nighttime sleep problems is pervasive across
the PD cognitive spectrum, from normal cognition to dementia, and is not independently associated with
cognitive impairment or deﬁcits in cognitive domains.
 2013 Published by Elsevier Ltd. Open access under CC BY-NC-ND license.enter, Department of Neuro-
icago, IL 60612, USA. Tel.: þ1
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cess under CC BY-NC-ND license.1. Introduction
Sleep disturbances are common in Parkinson’s disease (PD),
occurring in over 75% of patients and affecting both daytime and
nighttime function [1]. The etiology of daytime and nighttime sleep
problems in PD is likely multi-factorial, with contributions from
neurochemical and neuropathological changes associated with PD
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ders, and recurrent motor symptoms [2]. Prior studies of daytime
and nighttime sleep problems in PD have suggested that excessive
daytime sleepiness may be an integral part of PD pathology rather
than the result of poor nighttime sleep [3,4]; however, these studies
were not designed speciﬁcally to examine how daytime and
nighttime sleep disturbances relate to cognitive status or types of
cognitive deﬁcits in PD. Other studies have suggested an associa-
tion between excessive daytime sleepiness [5] and rapid eye
movement sleep behavior disorder (RBD) [6] with cognitive decline
or dementia in PD, but have focused generally on either daytime or
nighttime sleep problems individually, rather than their interde-
pendence. Thus, the interdependence of these sleep-wake prob-
lems across the cognitive spectrum of PD, from normal cognition to
dementia, merits investigation.
These knowledge gaps are particularly important because sleep
disturbances in PDmay have deleterious consequences on cognitive
function, an association that is well recognized in the general pop-
ulation and growing in the PD literature [7,8]. To our knowledge, no
studies have examined the relationships among daytime sleepiness,
nighttime sleep quality, and cognitive impairment across the full PD
cognitive spectrum including patients not only with normal cogni-
tion (PD-NC) and dementia (PDD), but also thosewithmild cognitive
impairment (PD-MCI), which recently has been deﬁned by a
Movement Disorder Society (MDS) task force [9] and may represent
a prodromal state heralding incipient dementia [10e12]. Identiﬁed
associations between speciﬁc features of sleep-wake dysfunction
and cognitive problems in PD may signify harbingers of cognitive
decline from PD-NC to PD-MCI and to PDD and ultimately, may lead
to interventions that could improve both sleep and cognitive
symptoms and modify risk factors for cognitive decline. Moreover,
studies of sleep-wake problems across a broad range of PD cognitive
functionmay reveal how these sleep disturbances vary not onlywith
cognitive status, but also with deﬁcits in speciﬁc cognitive domains.
Accordingly, the overall goal of our study was to investigate the
relationships among excessive daytime sleepiness, nighttime sleep
quality, andcognitive impairment inPD.Ourﬁrst aimwas to examine
self-reported daytime and nighttime sleep disturbances, measured
by, respectively, the Epworth Sleepiness Scale (ESS) [13] and Pitts-
burgh Sleep Quality Index (PSQI) [14] in a PD cohort represented by
PD-NC, PD-MCI, and PDD patients. These two scales are easily
administered, widely used, and deemed “Recommended” measures
by the MDS Sleep Scale Task Force for screening and measuring the
severity of sleep problems in PD [15]. Our second aimwas to inves-
tigate the relationship between sleep disturbances and speciﬁc
cognitive domains including attention and working memory, exec-
utive function, language, memory, and visuospatial function.2. Methods
2.1. Participants
Ninety-three PD patients were recruited from the Rush University Movement
Disorders clinic as part of a prospective study of clinical and neuroimaging markers
of PD cognitive impairment. PD patients met United Kingdom PD Society Brain Bank
criteria, had a disease duration of at least 4 years at the time of initial study eval-
uation, and were examined by a movement disorders neurologist (J.G.G.). Exclu-
sionary criteria were: atypical or secondary parkinsonism (e.g., dementia with Lewy
bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal
degeneration, or parkinsonism due to neuroleptic exposure, cerebrovascular dis-
ease, or known structural causes); severe or unstable depression; anticholinergic
medications (e.g., trihexyphenidyl, benztropine, tricyclic antidepressants); and
other medical/neurological causes of cognitive impairment (e.g., seizures, strokes,
head trauma, known untreated or unstable primary sleep disorders including
obstructive sleep apnea). In patients with dementia, all had motor symptoms for at
least one year prior to dementia onset. The study was approved by the Rush Uni-
versity Institutional Review Board in Chicago, IL; all participants gave written
informed consent to take part in the study.2.2. Evaluations
Clinical evaluations included assessments of demographics, disease-related fea-
tures, and medication use. Sleep measures included the ESS and PSQI, which were
administered to each patient to assess, respectively, daytime sleepiness and nighttime
sleepquality; forallpatients, regardlessof cognitive status, responses to thesleep scales
were corroborated with input from their informant (e.g., spouse, relative, friend, or
caregiver) during the interview. The study neurologist (J.G.G.) reviewed all question-
naires in their presence to resolve any ambiguities and determine ﬁnal scores.
Brieﬂy, the ESS is an 8-item questionnaire that measures one’s chances of
“dozing off” in different daytime situations over the past week; scores range from
0 to 24 with scores 10 indicating excessive daytime sleepiness [13]. The PSQI as-
sesses sleep quality over the past month; 19 individual items generate 7 component
scores, which are summed for a global score, ranging from 0 to 21 and with
scores > 5 indicating poor sleep [14]. Presence or absence of probable RBD (pRBD)
was examined with the question: “does the subject appear to act out his/her dreams
while sleeping [e.g., push or ﬂail their arms, shout, or scream]?” from the National
Alzheimer’s Coordinating Center Uniform Data Set [16]. Motor symptoms were
examined in the “on” state using the MDS-Uniﬁed Parkinson’s Disease Rating Scale
(MDS-UPDRS) Part III motor score and Hoehn and Yahr stage [17]. Medications taken
by patients for PD, sleep, mood, and cognition were recorded. PD medications were
converted to levodopa equivalent daily doses (LEDD) [18].
The neuropsychological evaluation included: 1) cognitive and mood assess-
ments, 2) a semi-structured interview with the patient and/or informant, and 3)
clinical impressions of the patient’s general cognitive function and functional abil-
ities. Cognitive assessments included the Folstein Mini-Mental State Examination
(MMSE) and the following individual tests grouped into 5 cognitive domains: (a)
attention and working memory (Digit span backwards and Letter Number
Sequencing from the Weschler Adult Intelligence Scale-III [WAIS-III], Trail making
Test-A), (b) executive function (animal naming in 1 min, Controlled Oral Word As-
sociation Test, and Goodglass and Kaplan Clock Drawing Test), (c) language (Boston
Naming Test, WAIS-III Similarities), (d) memory (3 trials of word list learning and
delayed recall from the Consortium to Establish a Registry for AD [CERAD], Logical
Memory I and II prose passages), and (e) visuospatial function (Benton Judgment of
Line Orientation, Goodglass and Kaplan Clock Copying Test). The Hamilton
Depression Rating Scale was used to assess depression.
2.3. Cognitive classiﬁcation
PD patients were classiﬁed into cognitive groups (PD-NC, PD-MCI, PDD) in a
consensus conference (neurologist, J.G.G.; neuropsychologists, G.T.S. and B.B.), using
semi-structured interviews with the patient and/or informant, clinical and neuro-
psychological data and MDS diagnostic criteria for both PD-MCI (Level II, compre-
hensive assessment) [9] and PDD [19]. Raw scores for cognitive tests were
transformed to z-scores based upon normative data from healthy, cognitively
normal controls at our center [20]. Impairment on neuropsychological tests was
demonstrated by z-scores of  1.5 on at least two neuropsychological tests (either
two impaired tests in one cognitive domain or one impaired test in two different
cognitive domains) [9]. Cognitive domain scores were calculated by averaging z-
scores for neuropsychological tests within speciﬁc domains.
2.4. Statistical analysis
Statistical analyses were performed using SAS 9.1 (Institute Inc., Cary, NC). De-
mographic and disease-related variables were compared across PD cognitive groups
using one-way analysis of variance (ANOVA), KruskaleWallis, Chi-square, or Fisher’s
Exact test, as appropriate. Analyses were adjusted for multiple comparisons using
Bonferroni corrections. Relationships between sleep scales, cognitive measures, and
medications were examined with Pearson or Spearman’s correlations or Wilcoxon
rank-sum test, as appropriate. Multivariate analysis was performed with propor-
tional odds model with odds ratios (OR), 95% conﬁdence intervals (CI), and Nagel-
kerke pseudo R-square (R2) reported. Statistical signiﬁcance was set at p < 0.05.
3. Results
3.1. Patient characteristics
Clinical and neuropsychological features of the cohort are pre-
sented in Table 1. There were no signiﬁcant differences among the
groups in age, gender, or education. Disease duration, however,
signiﬁcantly differed among the groups (F [2,90] ¼ 10.1,
p ¼ 0.0001), with post-hoc comparisons revealing longer disease
duration in PDD patients compared to PD-NC patients (p ¼ 0.001).
Motor severity differed signiﬁcantly among the groups, measured
byMDS-UPDRS Part III motor scores (F [2,90]¼ 9.9, p< 0.0001) and
Hoehn and Yahr stage (c2 ¼ 26.7, p < 0.0001). PDD patients had
Table 2
Sleep scale results for the PD cognitive groups.
PD-NC, n ¼ 28 PD-MCI, n ¼ 40 PDD, n ¼ 25 p value
ESS 7.9  3.7 8.8  5.3 12.1  5.0 0.005*
ESS 10, n (%) 9 (32.1) 18 (45.0) 19 (76.0) 0.005*
PSQI 6.2  2.8 7.0  3.2 7.0  3.3 0.60
PSQI > 5, n (%) 15 (53.6) 24 (60.0) 16 (64) 0.74
Results are expressed as mean  SD, unless otherwise noted.
Abbreviations: ESS ¼ Epworth Sleepiness Scale, PSQI ¼ Pittsburgh Sleep Quality
Index.
* Comparisons between PD-NC vs. PDD and PD-MCI vs. PDD.
Table 1
Demographic and clinical characteristics of our PD cohort.
PD-NC, n ¼ 28 PD-MCI, n ¼ 40 PDD, n ¼ 25 p value
Demographics
Age, y 72.1  6.1 73.5  6.2 75.5  6.8 0.15
Male, n (%) 20 (71.4) 32 (80) 17 (68) 0.52
Education, y 15.6  2.8 14.8  3.5 15.2  3.0 0.64
PD duration, y 8.9  3.0 10.1  4.3 13.8  5.1 <0.0001*
Motor and non-motor features
MDS-UPDRS motor score 31.3  8.4 37.3  12.1 45.5  13.9 <0.0001*
Hoehn and Yahr stage, median (range) 2.0 (2e3) 2.0 (2e5) 3.0 (2e5) <0.0001*
Probable RBD, n (%) 15 (53.6) 25 (62.5) 11 (44) 0.34
Medications
LEDD, mg/d 683.9  387.7 856.6  415.4 831.9  306 0.17
Dopamine agonist, n (%) 14 (50.0) 17 (42.5) 4 (16) 0.03þ
Amantadine, n (%) 3 (10.7) 10 (25) 1 (4) 0.05
Selegiline, n (%) 1 (3.6) 5 (12.5) 2 (8) 0.43
Sleep medication, n (%) 6 (21.4) 13 (32.5) 8 (32) 0.57
Antidepressant, n (%) 4 (14.3) 11 (27.5) 4 (16) 0.34
Cognitive enhancing medication, n (%) 1 (3.6) 5 (12.5) 13 (52) <0.0001*
Cognitive and neuropsychological features
Attention/working memory domain 0.34 (0.51) 1.41 (0.84) 2.87 (1.63) <0.0001^
Executive function domain 0.23 (67) 1.57 (0.82) 2.89 (0.90) <0.0001^
Language domain 0.11 (0.56) 0.71 (0.80) 1.92 (1.32) <0.0001^
Memory domain 0.34 (0.69) 1.14 (0.79) 3.11 (1.17) <0.0001^
Visuospatial domain 0.11 (0.82) 1.45 (1.32) 3.53 (2.01) <0.0001^
MMSE scores 28.6  1.1 27.6  1.7 20.1  6.2 <0.0001^
Hamilton depression rating scale 5.1  3.1 6.1  3.9 7.6  3.9 0.06
Results are expressed as mean  SD, unless otherwise noted.
Abbreviations: LEDD ¼ levodopa equivalent daily doses, MDS-UPDRS ¼ Movement Disorder Society-Uniﬁed Parkinson’s Disease Rating Scale, MMSE ¼ Mini-Mental State
Examination, RBD ¼ REM behavior disorder.
* Comparisons between PD-NC vs. PDD and PD-MCI vs. PDD;þ comparisons between PD-NC vs. PDD;^comparisons between PD-NC vs. PD-MCI, PD-NC vs. PDD and PD-MCI vs.
PDD.
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(p ¼ 0.02) patients and more advanced Hoehn and Yahr stages
compared to PD-NC (p ¼ 0.0001) and PD-MCI (p ¼ 0.0003). There
were no signiﬁcant differences among the groups regarding daily
levodopa equivalent doses. PD-NC patients, however, were more
frequently treated with dopamine agonists, compared to PDD pa-
tients (p ¼ 0.03). There were no signiﬁcant differences among the
groups for selegiline use, but there was a trend for greater aman-
tadine use in PD-MCI patients, compared to PDD patients (p¼ 0.05).
No signiﬁcant differences among the groups were seen regarding
medications used for sleep or mood. Of the 27 patients taking
medications for sleep disturbances, 7 received benzodiazepines (2
PD-NC, 4 PD-MCI,1 PDD patient); the remaining 20 usedmelatonin,
mirtazapine, quetiapine, trazadone or zolpidem. Presence of pRBD
symptoms was reported in 55% of our PD cohort, but did not differ
signiﬁcantly among cognitive groups (c2 ¼ 2.15, p ¼ 0.34).
There were signiﬁcant differences on raw neuropsychological
scores and cognitive domain z-scores among the cognitive groups
(p < 0.0001, all comparisons). Consistent with our cognitive group
deﬁnitions, cognitive performance was worst in PDD patients and
best in PD-NC patients (Supplemental Table). There were signiﬁcant
differences among the groups in their use of cognitive-enhancing
medications (i.e., cholinesterase inhibitors, memantine) (p < 0.001),
with PDD patients more frequently receiving these medications
compared to PD-NC (p< 0.0001) and PD-MCI (p¼ 0.001) patients. PD
patients had low Hamilton depression rating scale scores (mean
6.2  3.8), thereby indicating a non-depressed cohort.
3.2. Sleep scales in the PD cohort
The PD cohort exhibited daytime and nighttime sleep dysfunc-
tion, with mean ESS scores of 9.4  5.0 and mean PSQI scores,
6.7  3.1. Additionally, 49.5% had ESS scores 10, a cut-off signi-
fying excessive daytime sleepiness [13], and 59.1% had PSQIscores > 5, a cut-off designating poor nighttime sleep quality [14].
All combinations of clinically pertinent sleep-wake problems were
represented: poor nighttime sleep with (n ¼ 33) or without
excessive daytime sleepiness (n ¼ 22) and good nighttime sleep
with (n ¼ 13) or without excessive daytime sleepiness (n ¼ 25).
Overall, daytime and nighttime sleep abnormalities were not
strongly associated with each other, with ESS and PSQI scores
demonstrating modest, although statistically signiﬁcant, correla-
tions (r ¼ 0.22, p ¼ 0.03). Neither ESS nor PSQI scores correlated
signiﬁcantly with use of dopamine agonists (p ¼ 0.41, p ¼ 0.77,
respectively), levodopa doses (p ¼ 0.16, p ¼ 0.09, respectively), or
LEDD (p ¼ 0.55, p ¼ 0.34, respectively).
3.3. Relationships of the sleep scales to cognitive group
The two sleep scales differed in their relationship to PD cogni-
tive status on univariate analyses (Table 2, Fig. 1). Mean ESS scores
differed signiﬁcantly among the groups (F [2,90] ¼ 5.67, p ¼ 0.005)
with PDD patients having greater daytime sleepiness than PD-NC
and PD-MCI patients (p ¼ 0.006 and p ¼ 0.02, respectively). ESS
scores 10 occurred in 76% of PDD patients compared to 32.1% of
PD-NC and 45% of PD-MCI patients (c2 ¼ 10.72, p ¼ 0.005). In
Fig. 1. Sleep scales across the PD cognitive groups. Boxplots depicting median and inter-quartile ranges for the ESS and PSQI scales across the cognitive groups. * PD-NC vs. PDD,
p ¼ 0.004, x PD-MCI vs. PDD p ¼ 0.02.
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groups (F [2,90] ¼ 0.52, p ¼ 0.60). PSQI scores > 5 were frequent in
all cognitive groups, occurring in 53.6% of PD-NC, 60% of PD-MCI,
and 64% of PDD patients (c2 ¼ 0.61, p ¼ 0.74).
Table 3 depicts the multivariate analyses of the relationship
between ESS and PSQI, examined as both continuous measures
and binary measures, and PD cognitive status, adjusting for age,
PD duration, LEDD, Hoehn and Yahr stage, and presence/absence
of reported pRBD, in each model. Analyses with the sleep scales as
continuous measures revealed a signiﬁcant association with
Hoehn and Yahr (OR ¼ 3.24, CI ¼ [1.54, 6.81], p ¼ 0.002) but not
with age (p ¼ 0.06), PD duration (p ¼ 0.06), LEDD (p ¼ 0.57), pRBD
(p ¼ 0.51), or the ESS and PSQI scales (p ¼ 0.4, p ¼ 0.9, respec-
tively). With ESS and PSQI scores as binary measures, as deﬁned
above, there was a signiﬁcant association with Hoehn and Yahr
(OR ¼ 3.16, CI ¼ [1.51, 6.6], p ¼ 0.002) and mildly, but signiﬁcantly,
with age (OR ¼ 1.08, CI ¼ [1, 1.16], p ¼ 0.04), but not with PD
duration (p ¼ 0.06), LEDD (p ¼ 0.5), pRBD (p ¼ 0.65), or the ESS
and PSQI scales (p ¼ 0.19, p ¼ 0.56, respectively). Of the variables,
worse motor severity was most strongly related to worse PD
cognitive status.Table 3
Multivariate analyses of the sleep scales and PD cognitive groups.
Variable OR 95% CI p value
A. ESS and PSQI as continuous measures
ESS 1.04 0.94e1.15 0.4
PSQI 1.0 0.87e1.15 0.97
Age 1.07 0.99e1.15 0.06
PD duration 1.11 0.99e1.25 0.06
Hoehn and Yahr stage 3.24 1.54e6.81 0.002
Probable RBD 1.34 0.57e3.16 0.51
LEDD 1.03 0.92e1.17 0.57
B. ESS and PSQI as binary measures
ESS 10 vs. <10 1.91 0.72e5.08 0.19
PSQI >5 vs. 5 0.78 0.33e1.84 0.56
Age 1.08 1e1.16 0.04
PD duration 1.11 0.99e1.24 0.06
Hoehn and Yahr stage 3.16 1.51e6.6 0.002
Probable RBD 1.22 0.51e2.91 0.65
LEDD 1.04 0.92e1.17 0.5
A. Nagelkerke R-square ¼ 0.38.
B. Nagelkerke R-square ¼ 0.39.
Abbreviations: CI ¼ conﬁdence interval, ESS ¼ Epworth Sleepiness Scale,
LEDD ¼ levodopa equivalent daily doses, OR ¼ Odds ratio, PSQI ¼ Pittsburgh Sleep
Quality, RBD ¼ REM behavior disorder.3.4. Sleep scales and cognitive domains
The ESS and PSQI scales exhibited divergent relationships with
measures of global and domain-speciﬁc cognitive function. ESS
scores correlated with MMSE scores (r ¼ 0.31, p ¼ 0.002), whereas
PSQI scores did not (r ¼ 0.018, p ¼ 0.87). Moreover, ESS scores
correlated with impairments in cognitive domains of attention and
working memory (r ¼ 0.38, p < 0.0001), executive function
(r ¼ 0.34, p ¼ 0.001), memory (r ¼ 0.31, p ¼ 0.003), and visuo-
spatial abilities (r ¼ 0.35, p ¼ 0.001); ESS scores did not correlate
signiﬁcantly with the language domain. PSQI scores, however, did
not correlate with any cognitive domain scores: attention and
working memory (r ¼ 0.07, p ¼ 0.53), executive function (r ¼ 0.03,
p ¼ 0.78), language (r ¼ 0.06, p ¼ 0.58), memory (r ¼ 0.13,
p ¼ 0.21), and visuospatial abilities (r ¼ 0.004, p ¼ 0.97).
4. Discussion
Our study demonstrates that daytime sleepiness in PD, but not
nighttime sleep quality, as measured by the ESS and PSQI, respec-
tively, is associated with cognitive impairment in PD and worse
performance in cognitive domains of attention/working memory,
executive function, memory, and visuospatial function. To our
knowledge, our study is the ﬁrst to examine the interdependence of
self-reported daytime and nighttime sleep disturbances across the
full PD cognitive spectrum, spanning normal cognition to mild
cognitive impairment to dementia, and in particular, regarding
speciﬁc cognitive domain deﬁcits.
PDD patients had signiﬁcantly higher ESS scores reﬂecting
daytime sleepiness, compared to both PD-NC and PD-MCI patients,
despite similar nighttime sleep reports. The ﬁnding of higher ESS
scores in the PDD group extends other reports of close associations
between daytime sleepiness and dementia syndromes, including
Alzheimer’s disease, vascular dementia, and DLB patients [21e23]
and in a large population-based study of older adults, in which
excessive daytime sleepiness, but not insomnia or other nighttime
sleep complaints, was signiﬁcantly worse in the demented group
[22]. In our PD cohort, we also found that 45% of the PD-MCI pa-
tients had ESS scores 10, despite similar PSQI scores as the PD-NC
and PDD groups. Mean ESS scores for the PD-MCI group fell be-
tween scores of the PD-NC and PDD groups, ranging from 0 to 23
(maximum 24); the wide range of ESS scores in our PD-MCI group
may reﬂect the underlying heterogeneity in severity and pheno-
type of cognitive deﬁcits in PD-MCI. Longitudinal follow-up of our
PD-MCI patients, particularly thosewith higher baseline ESS scores,
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speciﬁc PD-MCI subtypes and effects of daytime sleepiness on
conversion to PD dementia.
One prior study investigated the relationship of daytime and
nighttime sleepdisturbances andneuropsychological functions inPD
but included only non-demented PD patients and focused on indi-
vidual neuropsychological tests [24]. Modest, but signiﬁcant, re-
lationships between the day and night subsections of the Scales for
Outcomes in PD-Sleep Scale (SCOPA) and the ESS and several indi-
vidual neuropsychological tests emerged. Worse ESS scores were
associated with poorer performance on Trail Making Test B-A ana-
lyses andchoice reactiontime tasks, thoughtherewasnorelationship
between SCOPA-day scores and cognitive performance; worse
SCOPA-night scores were associated with greater impairment on
Digit Span backwards and Logical Memory tests. Our study demon-
strated similar associations between excessive daytime sleepiness
and deﬁcits in attention/working memory and executive function,
but in contrast to this study [24], we did not ﬁnd signiﬁcant correla-
tions between nighttime sleep quality and any cognitive measure.
One other study reported that ESS scores did not correlate signiﬁ-
cantly with attention/executive function, memory, and psychomotor
function, but the primary emphasis of this study was on nighttime
functionwith actigraphy innon-dementedPDpatients; furthermore,
no details of the ESS scores or their relationships were provided [25].
Several key methodological differences between these studies and
ours could account for differences in results, including differences in
sleep and cognitive measures (i.e., scales used, comparison of
cognitive domains or individual neuropsychological tests) and PD
patient population (i.e., treated patients, inclusion of demented pa-
tients). Nonetheless, sleep-wake disturbances may relate differently
to speciﬁc elements of PD cognition, and further study of these re-
lationships may advance our understanding of their underlying
neural substrates and development of therapeutic interventions for
both sleep and cognition.
Our ﬁndings of abnormal ESS scores with or without poor PSQI
scores reinforce that excessive daytime sleepiness is not just a sec-
ondaryconsequenceofpoornighttime sleeporother features suchas
dopaminergic medications. Non-demented PD patients may exhibit
an increased drive to sleep or excessive daytime sleepiness, using
multiple sleep latency tests or ESS scores, without any signiﬁcant
changes in polysomnographic measures of sleep efﬁciency, total
sleep time, or REM sleep [3,4,26]. Thus, impaired wakefulness in PD
may reﬂect neuronal loss and Lewy body accumulation in the
brainstem, basal forebrain regions, hypothalamus, and thalamus and
accompanying neurochemical alterations in cholinergic, mono-
aminergic, dopaminergic, and histaminergic systems or the modu-
latory orexin/hypocretin systems [27]. Of note, similar
neuroanatomical regions and neurotransmitter systems to those
involved in sleep-wake regulation are implicated in attention, exec-
utive function, learning, and memory [19,27]. In our cohort, dopa-
minergic medications did not account for the greater daytime
sleepiness in cognitively impaired PD patients. While dopamine ag-
onistsmaybeassociatedwithexcessivedaytimesleepiness [28], they
were used less frequently by PDD patients, who represented the
sleepiest group with higher ESS scores compared to PD-NC and PD-
MCI patients. In addition, levodopa doses, which have been associ-
ated with sleepiness in some studies, did not differ signiﬁcantly
among our cognitive groups [29,30]. Our data, however, cannot
separate the effect of worse motor severity, as measured by Hoehn
andYahr stage, on excessive daytime sleepiness and cognitive status.
This may relate, in part, to underlying interactions between daytime
sleepiness and features of advanced PD, including both increased
motor severity and greater cognitive dysfunction. Additional studies
including larger PD cohorts and also representing broader distribu-
tions of ages, PD durations, andmotor stages may help elucidate therelationship of sleep-wake disturbances to these features and avoid
Type 2 errors that can occur with small sample sizes.
Strengths of our study include a large, well-deﬁned PD cohort, PD
diagnoses byMovement Disorder specialists, uniform data collection
with informant corroboration in all PD cases regardless of cognitive
status, and detailed cognitive and motor evaluations. In addition, we
used validated subjective sleep scales that have been recommended
by the MDS for use in PD and incorporated recently recommended
diagnostic criteria for PD-MCI andPDD.As the aimof our studywas to
examine the ESS and PSQI scales and to focus on patient/caregiver
perceptions of sleep aberrations,we did not include formal, objective
sleep and wakefulness tests (e.g., polysomnograms or multiple sleep
latency tests) as screening or outcome measures. Extension of our
study to include these types of measures is an opportunity for future
study. We acknowledge limitations including that the informants,
although they accompanied all PD patients, regardless of cognitive
status, andknew themwell, did not always include a bedpartner; the
presence/absence of pRBD symptomswas ascertained using a single-
item question, though this approach has been recently utilized [31];
and our university setting may limit generalizability to community
populations. Future studies may evaluate other features related to
sleep orwakefulness including speciﬁc questionnaires for co-morbid
sleep disorders (e.g., obstructive sleep apnea, restless legs syndrome,
periodic limb movements) or consumption of caffeine-containing
products.
We conclude that excessive daytime sleepiness is associatedwith
PD cognitive impairment, independent of nighttime sleep distur-
bances, asmeasured by the ESS and PSQI, respectively. Future studies
will benecessary todetermine the long-termcognitive consequences
of daytime sleepiness in PD, examine if these sleep disturbances
predict conversion of PD-NC to PD-MCI andPDD, andunderstand the
relationships among sleep, cognitive, and motor dysfunction.
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